MiSight 1 Day Safety Post-Approval Study

计划入组 2,400 人 · 首次发布于 2022 年 3 月 17 日

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

计划入组 900 人 · 首次发布于 2022 年 3 月 17 日

Assessing the Magnitude of Anisometropia in Patients Wearing Misight 1 Day Contact Lens

计划入组 50 人 · 首次发布于 2024 年 12 月 20 日

DAY-301

VRK1 Program (Day One Biopharmaceuticals)

1-naphthaleneacetic acid

C₁₂H₁₀O₂

Day, Robert

United States

NHI-1

United States

Day One Biopharmaceuticals

United States

CooperVision's MiSight 1 Day Becomes First Myopia Control Contact Lens Approved in Japan

China's NMPA Proposes Streamlined 30-Day Review Channel for Category 1 Innovative Drugs

Rolvedon Same-Day Dosing Shows Promise for Breast Cancer Patients in Phase 1 Trial